Haloperidol

CHEMBL54 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

375.9 g/mol

LogP

3.2

Phase

4

A first-generation antipsychotic medication widely used to treat schizophrenia, acute psychosis, severe agitation, and Tourette's syndrome by blocking dopamine D2 receptors in the brain. It is available in oral, injectable, and long-acting depot formulations. Long-term use requires monitoring for movement disorders, including tardive dyskinesia.

분자량

375.9000 g/mol

LogP

3.20

TPSA

40.50 Å²

리핀스키 5의 법칙

통과

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Pain Management Non-Small Cell Lung Cancer Alzheimer's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Chronic Kidney Disease Stroke Obesity Type 2 Diabetes Hypertension Breast Cancer Chronic Pain Heart Failure Prostate Cancer Colorectal Cancer

작용 기전

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1

InChI

InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2

Molecular Formula

C21H23ClFNO2

HBD / HBA

1 / 4

회전 가능 결합

6

무거운 원자

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

A first-generation antipsychotic medication widely used to treat schizophrenia, acute psychosis, severe agitation, and Tourette's syndrome by blocking dopamine D2 receptors in the brain. It is available in oral, injectable, and long-acting depot formulations. Long-term use requires monitoring for movement disorders, including tardive dyskinesia.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Haloperidol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL54. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3559. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Haloperidol PillFYI에서

구조

핵심 데이터

분자식: C21H23ClFNO2
동의어: 2

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.